Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015
Research

Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries

Ekaterina V. KurbatovaComments to Author , Tracy Dalton, Julia Ershova, Thelma E. Tupasi, Janice Campos Caoili, Martie L. van der Walt, Charlotte L. Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, HeeJin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, and J. Peter Cegielski
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, T. Dalton, J. Ershova, J. Campos Caoili, C. Kvasnovsky, J.P. Cegielski); Tropical Disease Foundation, Manila, the Philippines (T. Tupasi, J. Campos Caoili); Medical Research Council, Pretoria, South Africa (M. Van Der Walt, C. Kvasnovsky); National Institute of Health, Lima, Peru (M. Yagui); Socios en Salud Sucursal Perú, Lima (J. Bayona, C. Contreras); Riga East University Hospital Centre of Tuberculosis and Lung Diseases, Riga, Latvia (V. Leimane); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA (L.E. Via); University of Cape Town, Cape Town, South Africa (L.E. Via):; Korean Institute of TB, Seoul, South Korea (H. Kim); Ministry of Public Health, Bangkok, Thailand (S. Akksilp); Orel Oblast Tuberculosis Dispensary, Orel, Russia (B.Y. Kazennyy); Vladimir Oblast Tuberculosis Dispensary, Vladimir, Russia (G.V. Volchenkov); Taiwan Centers for Disease Control, Taipei, Taiwan (R. Jou); Tartu University Hospital, Tartu, Estonia (K. Kliiman); Russian Academy of Medical Sciences, Moscow, Russia (O.V. Demikhova)

Main Article

Table 4

Association of patient characteristics with candidacy for a short (9-month) regimen or a BDQ-containing regimen among patients with MDR TB*

Characteristic Patient candidate, no. (%)
p value
Total Short regimen BDQ-containing regimen
Sex
M 804 613 (76.2) 191 (23.8) 0.72
F 450 339 (75.3) 111 (24.7)
Employment status
Unemployed 475 328 (69.1) 147 (30.9) <0.001
Disabled, retired, student, housewife 192 150 (78.1) 42 (21.9) 0.37
Employed 581 471 (81.1) 110 (18.9)
History of imprisonment
Yes 81 50 (61.7) 31 (38.3) 0.001
Unknown 181 130 (71.8) 51 (28.2) 0.08
No 992 772 (77.8) 220 (22.2)
Homeless
Yes 29 21 (72.4) 8 (27.6) 0.54
Unknown 137 91 (66.4) 46 (33.6) 0.005
No 1,088 840 (77.2) 248 (22.8)
Alcohol abuse
Yes 186 108 (58.1) 78 (41.9) <0.001
Unknown 52 31 (59.6) 21 (40.4) <0.001
No 1,016 813 (80) 203 (20)
HIV status
Positive 159 108 (67.9) 51 (32.1) 0.88
Unknown 468 422 (90.2) 46 (9.8) <0.001
Negative 627 422 (67.3) 205 (32.7)
Any co-morbidity other than HIV infection
Yes 335 257 (76.7) 78 (23.3) 0.69
No 919 695 (75.6) 224 (24.4)
Classification by prior treatment history
Received first-line drugs 879 719 (81.8) 160 (18.2) <0.001
Received second-line injectable drugs 185 103 (55.7) 82 (44.3) 0.04
New case 168 112 (66.7) 56 (33.3)
Classification by prior TB treatment outcome
Relapse 181 124 (68.5) 57 (31.5) 0.66
Failure, loss to follow up, change to second-line regimen 598 444 (74.2) 154 (25.8) 0.04
Chronic 190 172 (90.5) 18 (9.5) <0.001
Unknown 119 102 (85.7) 17 (14.3) <0.001
New case 166 110 (66.3) 56 (33.7)
Body mass index
<18.5 471 369 (78.3) 102 (21.7) 0.12
>18.5 783 583 (74.5) 200 (25.5)
Site of TB disease
Extrapulmonary and pulmonary 57 45 (78.9) 12 (21.1) 0.59
Pulmonary only 1,195 906 (75.8) 289 (24.2)
Bilateral TB disease
Yes 993 748 (75.3) 245 (24.7) 0.48
No 236 183 (77.5) 53 (22.5)
Cavities on chest radiograph
Unilateral 477 339 (71.1) 138 (28.9) <0.001
Bilateral 293 210 (71.7) 83 (28.3) <0.001
No 484 403 (83.3) 81 (16.7)
AFB smear at the start of MDR treatment
Positive 1,063 810 (76.2) 253 (23.8) 0.37
Negative 155 113 (72.9) 42 (27.1)

*Row percentages show proportion of patients with each characteristic that would be candidates for a particular regimen. AFB, acid-fast bacilli; BDQ, bedaquiline; MDR, multidrug-resistant; TB, tuberculosis.Bold type indicates statistical significance.

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external